Cefpodoxime proxetil is an oral prodrug of the third-generation cephalosporin antibiotic cefpodoxime, which is hydrolyzed in vivo to the active form. It exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria by inhibiting bacterial cell wall synthesis. This pharmaceutical intermediate is used in the formulation of medications for treating respiratory tract infections (e.g., bronchitis, pneumonia, sinusitis), urinary tract infections (e.g., cystitis, pyelonephritis), skin and soft tissue infections (e.g., wounds, abscesses), and ear infections (e.g., otitis media), including in pediatric applications. Supplied as a faint yellow powder, it conforms to the reference structure as confirmed by infrared spectroscopy and NMR.